Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:AKRO NASDAQ:LNTH NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$69.39-1.2%$69.28$47.86▼$107.37$3.90B0.28604,355 shs518,763 shsAKROAkero Therapeutics$46.73-0.4%$50.59$21.34▼$58.40$3.75B-0.281.01 million shs497,456 shsLNTHLantheus$54.90-1.1%$69.20$47.25▼$118.21$3.77B0.142.62 million shs1.03 million shsVALNValneva$8.85+0.1%$7.73$3.62▼$12.25$752.23M1.77150,849 shs35,793 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-1.22%-2.65%-3.01%+9.16%+0.13%AKROAkero Therapeutics-0.45%-5.08%-2.07%-8.41%+75.48%LNTHLantheus-1.08%-5.69%-23.58%-27.29%-49.96%VALNValneva+0.11%-23.97%+15.69%+40.92%+16.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.1233 of 5 stars3.60.00.00.03.72.50.0AKROAkero Therapeutics4.0811 of 5 stars3.52.00.04.74.20.80.0LNTHLantheus4.7748 of 5 stars4.41.00.04.23.22.51.9VALNValneva2.0745 of 5 stars3.53.00.00.02.40.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$114.3164.73% UpsideAKROAkero Therapeutics 3.00Buy$81.5774.56% UpsideLNTHLantheus 2.71Moderate Buy$105.5092.17% UpsideVALNValneva 3.00Buy$15.3373.26% UpsideCurrent Analyst Ratings BreakdownLatest VALN, LNTH, ACLX, and AKRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025VALNValnevaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$14.008/25/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/19/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.008/11/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Hold$111.00 ➝ $63.008/7/2025LNTHLantheusJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$112.00 ➝ $73.008/7/2025LNTHLantheusMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$120.00 ➝ $70.008/4/2025AKROAkero TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy8/4/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/4/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$76.007/31/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$93.00 ➝ $133.007/16/2025LNTHLantheusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$56.98M67.54N/AN/A$7.07 per share9.81AKROAkero TherapeuticsN/AN/AN/AN/A$12.82 per shareN/ALNTHLantheus$1.53B2.43$7.02 per share7.82$17.16 per share3.20VALNValneva$196.33M3.84$0.10 per share90.47$2.49 per share3.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)AKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)LNTHLantheus$312.44M$3.7614.608.70N/A17.82%34.06%19.10%11/5/2025 (Estimated)VALNValneva-$13.25M-$0.98N/AN/AN/A-33.87%-34.78%-13.43%11/6/2025 (Estimated)Latest VALN, LNTH, ACLX, and AKRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025VALNValneva-$0.27-$0.16+$0.11-$0.16$46.28 million$54.84 million8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81AKROAkero Therapeutics0.0212.6612.66LNTHLantheus0.494.294.07VALNValneva0.662.271.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%AKROAkero TherapeuticsN/ALNTHLantheus99.06%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%AKROAkero Therapeutics7.07%LNTHLantheus1.50%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableLNTHLantheus70067.99 million66.97 millionOptionableVALNValneva70085.09 million72.41 millionNot OptionableVALN, LNTH, ACLX, and AKRO HeadlinesRecent News About These CompaniesFDA License Suspension Ends Use of Chikungunya Vaccine Ixchiq in USAugust 29 at 7:21 PM | infectiousdiseaseadvisor.comIHC Wainwright Reiterates "Buy" Rating for Valneva (NASDAQ:VALN)August 27 at 2:41 PM | marketbeat.comValneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?August 27 at 12:53 PM | marketbeat.comFDA Suspends Valneva Vaccine’s License Following New Reports of Adverse EventsAugust 27 at 9:29 AM | medcitynews.comMValneva has biologics license withdrawn for chikungunya vaccineAugust 27 at 4:28 AM | thepharmaletter.comTAs Chikungunya Spreads Worldwide, FDA Halts Use of Only U.S.-Approved VaccineAugust 26, 2025 | managedhealthcareexecutive.comMValneva Outlook: Safety Blow To Ixchiq And Valuation ConcernsAugust 26, 2025 | seekingalpha.comValneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The ImpactAugust 26, 2025 | msn.comFDA: Valneva’s Ixchiq unpicked for safety in chikungunyaAugust 25, 2025 | bioworld.comBUS suspends chikungunya vaccine Ixchiq over 'serious' side effects: ValnevaAugust 25, 2025 | e.vnexpress.netEFDA Suspends U.S. License of Chikungunya VaccineAugust 25, 2025 | purdueexponent.orgPValneva stock tumbles as FDA suspends license for IXCHIQ vaccineAugust 25, 2025 | za.investing.comValneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.August 25, 2025 | marketwatch.comFDA does a 180, suspending use of Valneva's chikungunya vaccineAugust 25, 2025 | fiercepharma.comFSafety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In USAugust 25, 2025 | benzinga.comFDA suspends license for Valneva’s chikungunya shotAugust 25, 2025 | biopharmadive.comBValneva Reveals FDA’s Decision to Suspend Ixchiq’s License in the U.S.August 25, 2025 | pharmexec.comPFDA suspends license for chikungunya vaccine Ixchiq over serious safety concernsAugust 25, 2025 | cidrap.umn.eduCValneva shares tumble after suspension of US chikungunya vaccine licenceAugust 25, 2025 | msn.comKeurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On MondayAugust 25, 2025 | benzinga.comJohnson Fistel Investigates Valneva Following FDA SuspensionAugust 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVALN, LNTH, ACLX, and AKRO Company DescriptionsArcellx NASDAQ:ACLX$69.39 -0.86 (-1.22%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$69.44 +0.05 (+0.07%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Akero Therapeutics NASDAQ:AKRO$46.73 -0.21 (-0.45%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$46.65 -0.08 (-0.17%) As of 08/29/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Lantheus NASDAQ:LNTH$54.90 -0.60 (-1.08%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$55.54 +0.65 (+1.17%) As of 08/29/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Valneva NASDAQ:VALN$8.85 +0.01 (+0.11%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.84 -0.01 (-0.16%) As of 08/29/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
